SCHEMBL26142004

SCHEMBL26142004

COc1cc(-c2cn(C)c(=O)c3ccccc23)cc(OC)c1OC

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 14/20 0.68
BRD9 Q9H8M2 5/20 0.68
BRD7 Q9NPI1 5/20 0.68
BRD2 P25440 2/20 0.68
KDR P35968 2/20 0.57
PDGFRB P09619 2/20 0.53
PLK4 O00444 1/20 0.53
AURKA O14965 1/20 0.53
NUAK1 O60285 1/20 0.53
INSR P06213 1/20 0.53
CDK4 P11802 1/20 0.53
BRAF P15056 1/20 0.53
CCND1 P24385 1/20 0.53
CDK2 P24941 1/20 0.53
FLT4 P35916 1/20 0.53
FLT3 P36888 1/20 0.53
PTK2 Q05397 1/20 0.53
AURKB Q96GD4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27263485 0.88 BRD4 (0.68) BRD4BRD9BRD7BRD2
SCHEMBL26142003 0.87 BRD4 (0.67) BRD4BRD9BRD7BRD2
SCHEMBL23783259 0.85 BRD4 (0.64) BRD4BRD9BRD7BRD2
SCHEMBL30032023 0.85 BRD4 (0.64) BRD4BRD9BRD7BRD2
SCHEMBL25102275 0.82 BRD9 (0.71) BRD4BRD9BRD7BRD2KDR
SCHEMBL26142001 0.82 BRD4 (0.78) BRD4BRD9BRD7BRD2
SCHEMBL15815882 0.81 BRD4 (0.51) BRD4BRD9BRD7BRD2KDR
SCHEMBL19869875 0.81 BRD4 (1.00) BRD4BRD9BRD7BRD2
SCHEMBL25846135 0.79 BRD4 (0.58) BRD4BRD9BRD7BRD2
SCHEMBL29848975 0.78 BRD4 (0.63) BRD4BRD9BRD7BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20230331722-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-10-19 US disclosed
US-20230142883-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331722-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 BRD4 42/4885BRD9 290/4885BRD7 149/4885
US-20230142883-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 BRD4 42/4885BRD9 290/4885BRD7 149/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 BRD4 42/4885BRD9 290/4885BRD7 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.